CY1114241T1 - Ν-αρυλοσουλφονυλ-3-αμινοαλκοξυινδολια - Google Patents

Ν-αρυλοσουλφονυλ-3-αμινοαλκοξυινδολια

Info

Publication number
CY1114241T1
CY1114241T1 CY20131100698T CY131100698T CY1114241T1 CY 1114241 T1 CY1114241 T1 CY 1114241T1 CY 20131100698 T CY20131100698 T CY 20131100698T CY 131100698 T CY131100698 T CY 131100698T CY 1114241 T1 CY1114241 T1 CY 1114241T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutically acceptable
acceptable salts
compounds
forms
general formula
Prior art date
Application number
CY20131100698T
Other languages
English (en)
Inventor
Venkata Satya Nirogi Ramakrishna
Vikas Shreekrishna Shirsath
Rama Sastri Kambhampati
Venkata Satya Veerabhadra Vadlamudi Rao
Venkateswarlu Jasti
Original Assignee
Suven Life Sciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Limited filed Critical Suven Life Sciences Limited
Publication of CY1114241T1 publication Critical patent/CY1114241T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

Abstract

Η παρούσα εφεύρεση περιγράφει υποκατεστημένα 3-Αμινοαλκοξυινδόλια, ενώσεις του γενικού τύπου (Ι), τα στερεοϊσομερή της, τα ραδιοϊσότοπα της, τις γεωμετρικές της μορφές, τα Ν-οξείδια της, τις πολυμορφικές της μορφές, τα φαρμακευτικώς αποδεκτά άλατα της, τις φαρμακευτικώς αποδεκτές μορφές της που είναι ενωμένες χημικά με διαλύτες, τους χρήσιμους βιοενεργούς μεταβολίτες της και οιονδήποτε κατάλληλο συνδυασμό των ανωτέρω. Η εφεύρεση αποκαλύπτει επίσης τις μεθόδους παρασκευής τέτοιων ενώσεων του γενικού τύπου (Ι), των στερεοϊσομερών της, των ραδιοϊσοτόπων της, των γεωμετρικών της μορφών, των Ν-οξειδίων της, των πολυμορφικών της μορφών, των φαρμακευτικώς αποδεκτών αλάτων της, των φαρμακευτικώς αποδεκτών μορφών της που είναι ενωμένες χημικά με διαλύτες, των χρήσιμων βιοενεργών μεταβολιτών της και επίσης περιλαμβάνει οιονδήποτε κατάλληλο συνδυασμό των ανωτέρω. Περαιτέρω περιγράφονται διάφορες μέθοδοι χορήγησης αυτών των ενώσεων του γενικού τύπου (Ι), δηλαδή οι φαρμακευτικώς αποδεκτές δοσολογικές μορφές, η σύνθεση τους και η χρήση τους είτε θεραπευτικά είτε διαγνωστικά.
CY20131100698T 2002-11-28 2013-08-14 Ν-αρυλοσουλφονυλ-3-αμινοαλκοξυινδολια CY1114241T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN883MA2002 2002-11-28
EP03778739.7A EP1567492B1 (en) 2002-11-28 2003-11-25 N-arylsulfonyl-3-aminoalkoxyindoles

Publications (1)

Publication Number Publication Date
CY1114241T1 true CY1114241T1 (el) 2016-08-31

Family

ID=34362365

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100698T CY1114241T1 (el) 2002-11-28 2013-08-14 Ν-αρυλοσουλφονυλ-3-αμινοαλκοξυινδολια

Country Status (18)

Country Link
US (2) US7507835B2 (el)
EP (1) EP1567492B1 (el)
JP (2) JP4782425B2 (el)
KR (1) KR100776118B1 (el)
CN (2) CN102249981A (el)
AU (1) AU2003285759B2 (el)
BR (1) BRPI0315958B8 (el)
CA (1) CA2507505C (el)
CY (1) CY1114241T1 (el)
EA (1) EA009193B1 (el)
ES (1) ES2425143T3 (el)
MX (1) MXPA05005700A (el)
NO (1) NO331805B1 (el)
NZ (1) NZ540842A (el)
PT (1) PT1567492E (el)
SI (1) SI1567492T1 (el)
WO (1) WO2004048328A2 (el)
ZA (1) ZA200504044B (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005700A (es) * 2002-11-28 2005-08-16 Suven Life Sciences Ltd N-arilsulfonil-3-aminoalcoxiindoles.
SI1581538T1 (sl) * 2002-12-18 2007-08-31 Suven Life Sciences Ltd Tetraciklični 3-substituirani indoli z afiniteto za receptor serotonina
KR101049868B1 (ko) 2004-01-02 2011-07-19 수벤 라이프 사이언시스 리미티드 신규한 인데노[2,1ａ]인덴 및 이소인돌[2,1-ａ]인돌
DE602005018554D1 (de) 2005-08-12 2010-02-04 Suven Life Sciences Ltd Aminoarylsulfonamidderivate als funktionelle 5-ht6-liganden
WO2007020654A1 (en) 2005-08-16 2007-02-22 Suven Life Sciences An improved process for the preparation of losartan
KR100724095B1 (ko) * 2005-10-21 2007-06-04 한국표준과학연구원 정밀 전류, 전압 및 전력 측정장치
KR101103023B1 (ko) 2007-01-08 2012-01-05 수벤 라이프 사이언시스 리미티드 ５­（헤테로시클릴）알킬­ｎ­（아릴술포닐）인돌 화합물 및 ５­ｈｔ６ 리간드로서 이들의 용도
EP1947085A1 (en) * 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
WO2008136017A1 (en) * 2007-05-03 2008-11-13 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
ES2370680T3 (es) * 2007-10-26 2011-12-21 Suven Life Sciences Limited Compuestos de aminoarilsulfonamida y su empleo como ligandos de 5-ht6.
AR072297A1 (es) * 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
EP2149573A1 (en) * 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Substituted indole sulfonamide compounds their preparation and use as medicaments
AU2009294181B2 (en) 2008-09-17 2011-11-17 Suven Life Sciences Limited Aryl sulfonamide amine compounds and their use as 5-HT6 ligands
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
NZ601284A (en) 2010-01-05 2014-03-28 Suven Life Sciences Ltd Sulfone compounds as 5-ht6 receptor ligands
EP2932922B1 (en) * 2012-12-13 2018-09-05 Olympus Corporation Treatment device
DE102013013602A1 (de) * 2013-08-19 2015-02-19 Trützschler GmbH + Co KG Textilmaschinenfabrik Vorrichtung an einer Karde oder Krempel für Baumwolle, Chemiefasern u. dgl. mit einer drehbaren Abstreifwalze
JP6454346B2 (ja) 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族複素環式化合物及び医薬におけるその応用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE111890C (el)
US723550A (en) * 1902-09-15 1903-03-24 Eagle Lock Co Padlock.
CH489497A (de) * 1967-01-25 1970-04-30 Geigy Ag J R Verfahren zur Herstellung von neuen Indolderivaten
GB1306230A (el) 1969-05-27 1973-02-07
US3860608A (en) * 1969-05-27 1975-01-14 Novo Terapeutisk Labor As 3-aminoalkyloxyindoles
US3860609A (en) * 1969-05-27 1975-01-14 Novo Terapeutisk Labor As 3-aminoalkyloxyindoles
ZA795239B (en) 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
JPS57200362A (en) 1981-06-05 1982-12-08 Mitsui Toatsu Chem Inc Preparation of indoxyl
GB8600397D0 (en) 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
JPH01139564A (ja) * 1987-08-31 1989-06-01 Terumo Corp Ｎ−置換インドールエステル化合物、その製造法ならびに該化合物を用いた試験組成物および試験具
GB8724912D0 (en) 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
CA2042295A1 (fr) 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
CZ288351B6 (en) 1990-06-07 2001-05-16 Astrazeneca Ab Nitrogenous heterocyclic compound, process of its preparation and use as well as a medicament containing thereof
CZ283018B6 (cs) 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
GB9113802D0 (en) 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments
GB9210400D0 (en) 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
KR940007001A (ko) 1992-09-16 1994-04-26 최승주 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제
IL130169A (en) 1999-05-27 2006-08-20 Neurim Pharma 1991 Indole derivatives, and pharmaceutical preparations, skin protection preparations, and cosmetics containing them
FR2799757B1 (fr) 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2821843B1 (fr) * 2001-03-12 2003-05-09 Servier Lab Nouveaux derives d'isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE60317333T2 (de) * 2002-06-21 2008-08-28 Suven Life Sciences Ltd. Tetracyklische arylsulfonylindole mit affinität zum serotonin rezeptor
MXPA05000315A (es) * 2002-07-22 2005-03-31 Basf Ag Mezclas de accion herbicida sinergetica.
MXPA05005700A (es) * 2002-11-28 2005-08-16 Suven Life Sciences Ltd N-arilsulfonil-3-aminoalcoxiindoles.

Also Published As

Publication number Publication date
CA2507505A1 (en) 2004-06-10
NO331805B1 (no) 2012-04-10
ZA200504044B (en) 2006-07-26
WO2004048328A2 (en) 2004-06-10
AU2003285759B2 (en) 2010-01-28
US7718690B2 (en) 2010-05-18
AU2003285759A1 (en) 2004-06-18
EP1567492A2 (en) 2005-08-31
KR20050083963A (ko) 2005-08-26
MXPA05005700A (es) 2005-08-16
BR0315958A (pt) 2005-09-13
NO20052825L (no) 2005-08-25
PT1567492E (pt) 2013-07-22
CN1720227A (zh) 2006-01-11
JP2011116769A (ja) 2011-06-16
US20090131507A1 (en) 2009-05-21
JP4782425B2 (ja) 2011-09-28
WO2004048328A3 (en) 2004-10-28
EA200500882A1 (ru) 2005-12-29
NZ540842A (en) 2008-05-30
BRPI0315958B8 (pt) 2021-05-25
JP2006511506A (ja) 2006-04-06
EA009193B1 (ru) 2007-12-28
US20060173193A1 (en) 2006-08-03
CA2507505C (en) 2011-10-04
CN102249981A (zh) 2011-11-23
BRPI0315958B1 (pt) 2018-06-26
US7507835B2 (en) 2009-03-24
EP1567492B1 (en) 2013-05-22
KR100776118B1 (ko) 2007-11-15
ES2425143T3 (es) 2013-10-11
SI1567492T1 (sl) 2013-07-31
NO20052825D0 (no) 2005-06-10

Similar Documents

Publication Publication Date Title
CY1114241T1 (el) Ν-αρυλοσουλφονυλ-3-αμινοαλκοξυινδολια
CY1111876T1 (el) Νεες πυρρολες με υπολiπiδaiμiκες και υποχοληστερολαιμικες δραστικοτητες, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που τις περιεχουν και η χρηση αυτων στην ιατρικη
CY1114708T1 (el) Παραγωγα πυραζολο-κιναζολινης, διαδικασια για την παρασκευη τους και η χρηση τους ως αναστολεων κινασης
DK1353911T3 (da) Antivirale midler
CY1105387T1 (el) Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
TR200201057T2 (tr) P38 protein kinazı inhibitörleri olarak heteroalkilamino ikameli bisiklik nitrojen heterosaykılları.
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
CY1105621T1 (el) Νεα ετεροκυκλικα παραγωγα φθορογλυκοζιτου, φαρμακα που περιεχουν τις ενωσεις αυτες και η χρηση τους
CY1108894T1 (el) Νεα παραγωγα βενζιμιδαζολης
CY1112086T1 (el) Συνδυασμος γλυκοπυρρολικου αλατος και ενος αγωνιστη βητα2 αδρενεργικων υποδοχεων
CY1111425T1 (el) ΠΑΡΑΓΩΓΑ ΤΗΣ ΠΥΡΙΔΟ[2,1-a]-ΙΣΟΚΙΝΟΛΙΝΗΣ ΩΣ DPP-IV ΑΝΑΣΤΟΛΕΙΣ
PA8592001A1 (es) Activadores de glocoquinasa heteroaromaticos de seis miembros 5-sustituidos
SE9904508D0 (sv) New compounds
CY1106297T1 (el) Παραγωγα πυραζολης χρησιμα ως αναστολεις κινασης πρωτεϊνης
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
MXPA03001431A (es) Polimeros de un analogo de epotilona.
DE602005023185D1 (de) Prodrugs mit neuen biospaltbaren verbindern
BRPI0315959C1 (pt) composto, composição farmacêutica, uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto
NO985518D0 (no) Morfinanderivater og medisinsk anvendelse derav
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
ATE352543T1 (de) Ein dioxino(2,3-g)chinolin-9-carbonsäure derivat als nk3 rezeptor antagonist
CY1105019T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
CY1108890T1 (el) 7-ιμινο παραγωγα καμπτοθεκινης που εχουν αντιογκικη δραση